Stockreport

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

Tango Therapeutics, Inc.  (TNGX) 
PDF STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of [Read more]